Drug Profile


Alternative Names: DG-031

Latest Information Update: 30 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer deCODE genetics
  • Class Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Myocardial infarction

Most Recent Events

  • 31 Dec 2012 deCODE genetics has been acquired by Amgen
  • 12 Mar 2008 Veliflapon is available for licensing (
  • 05 Oct 2006 Suspended - Phase-III for Myocardial infarction in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top